<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03686059</url>
  </required_header>
  <id_info>
    <org_study_id>hamaky1</org_study_id>
    <nct_id>NCT03686059</nct_id>
  </id_info>
  <brief_title>Outcome of Omega 3 FA and Punctal Plugs on Ocular Surface Disease</brief_title>
  <official_title>Outcome of Concomitant Use of Punctal Plugs and Omeg 3 Fatty Acids on Ocular Surface Disease in Patients Using Systemic Isotretinoin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benha University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Benha University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ocular surface disease is a common adverse effect of systemic isotretinoin therapy.

      The investigators consider that punctal plugs and Omega 3 is a good line for treatment of
      ocular surface disease associated with systemic isotretinoin therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjective and objective evaluation of ocular surface disease was done at baseline ,1 and 3
      months of the study .
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2, 2018</start_date>
  <completion_date type="Actual">November 20, 2019</completion_date>
  <primary_completion_date type="Actual">November 15, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Break up Time at baseline and during the study</measure>
    <time_frame>3 months</time_frame>
    <description>fluorescein sodium stripes will be used for measurement of Break up Time in seconds</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Ocular Surface Disease</condition>
  <arm_group>
    <arm_group_label>punctal plug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SOFT PLUG速 Preloaded Silicone Plugs by OASIS速</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SOFT PLUG速 Preloaded Silicone Plugs by OASIS速 plus Daily intake of DHA (docosahexaenoic acid)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no medication was given</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega 3</intervention_name>
    <description>daily intake of 250 mg</description>
    <arm_group_label>Combined</arm_group_label>
    <other_name>docosahexaenoic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>punctal plug</intervention_name>
    <description>punctal plug will be inserted in inferior punctum</description>
    <arm_group_label>Combined</arm_group_label>
    <arm_group_label>punctal plug</arm_group_label>
    <other_name>OASIS SOFT PLUG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  systemic isotretinoin therapy

        Exclusion Criteria:

          -  systemic or ocular diseases ,previous ocular surgery, corneal pathology and contact
             lens wearer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ACDS</name>
      <address>
        <city>Abu Dhabi</city>
        <zip>37496</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Arab Emirates</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 25, 2018</study_first_submitted>
  <study_first_submitted_qc>September 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2018</study_first_posted>
  <last_update_submitted>November 24, 2019</last_update_submitted>
  <last_update_submitted_qc>November 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Benha University</investigator_affiliation>
    <investigator_full_name>Tarek Roshdy mohamed Mahgoub ELhamaky</investigator_full_name>
    <investigator_title>lecturer of ophthalmology</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

